Before GLP-1, Diagnose the Human

Why Comprehensive Obesity Assessment Should Come Before Semaglutide, Tirzepatide, or Any Weight-Loss Prescription

GLP-1 medications such as semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. and tirzepatide have changed obesity medicine. For appropriately selected patients, they can produce substantial weight loss, improve metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., and reduce important obesity-related risks. Their effectiveness is not seriously in question.

What deserves much more scrutiny is the medical process that takes place before the prescription is written. Across the United States, GLP-1 treatment has become extraordinarily easy to obtain. A patient may encounter an advertisement, complete an online questionnaire, report a height and weight, answer several contraindication questions, and receive a prescription soon afterward. That process may satisfy the requirements of a particular telehealthMedical care delivered via phone or video. platform and, depending on the circumstances, may be legally permissible. But it is very different from asking the broader clinical question that obesity medicine increasingly demands: Why has this patient's weight changed, what else is happening across the patient's health, and what treatment strategy best fits that individual?

At Fountain Health in New York City, we believe the distinction matters. Weight gain is not simply a number to be lowered. It may sit at the intersection of metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., mental health, sleep, eating behavior, medications, hormonal or endocrine conditions, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., physical activity, body compositionThe balance of muscle, fat, and water in the body., and other biological factors. A GLP-1 medication may ultimately be the right treatment. But the decision should follow an effort to understand the person, rather than replace that effort.

GLP-1 Is a Treatment. Obesity Requires a Diagnosis.

Weight-loss drugs can be extraordinary medicine. But a prescription should come after understanding why a patient is gaining weight, not before.

Something unusual has happened in obesity medicine. A patient gains 30 or 40 pounds. She searches for help. Increasingly, the first question is not Why is this happening? It is Do you qualify for a GLP-1?

In July 2026, Yale researchers published a secret-shopper study in JAMA. They created a simulated patient who qualified for a GLP-1 and tried to obtain one from 49 online sellers. The results are remarkable:

• 45 of 49 — 91.8% — prescribed a GLP-1.
• 34 actually mailed the drug.
• Only 13 of 49 required a video visit.
• Only 3 required a telephone call.
• Just 53% asked about diet and physical activity.
• Only 55% asked about eating disorders.

The researchers concluded that some platforms appeared to prioritize rapid prescribing over comprehensive care. That is backwards.

Consider two hypothetical patients, both with a BMI of 31. One sleeps well, exercises regularly, has relatively normal metabolic markers, no significant psychiatric history and describes persistent hunger despite years of structured attempts at weight loss.

The other sleeps five hours a night, has worsening depressionA prolonged low mood that interferes with life., episodes of uncontrolled eating, recently started a medication associated with weight gain and has developed signs of metabolic dysfunction.

The number on the scale may be similar, but the patients are not. Yet, a prescription-first model can reduce both stories to the same sequence: height, weight, contraindication questionnaire, prescription.

Modern obesity medicine increasingly says we should do something very different. The American Diabetes Association's 2026 Standards of Care in Overweight and Obesity recommend a comprehensive evaluation after diagnosing overweight or obesity and before building the management plan. The recommended assessment includes weight history, factors contributing to weight gain, concurrent medical and psychological conditions, eating patterns, physical activity, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., sleep, medications, substance use, social circumstances and obesity-related complications.

That is not alternative medicine. It is the current direction of mainstream obesity medicine.

Weight gain is often a systems problem

Human weight regulation sits at the intersection of metabolism, appetite signaling, reward pathways, sleep, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., hormones, medications, movement, nutrition and mental health.

DepressionA prolonged low mood that interferes with life., for example, does not simply coexist with obesity. Longitudinal research has found a relationship in both directions: people with obesity have increased subsequent risk of depression, while depression is associated with increased risk of subsequently developing obesity.

Sleep can matter more than patients realize. In a randomized clinical trial of adults with overweight who habitually slept fewer than 6.5 hours a night, participants assigned to extend their sleep reduced energy intake by approximately 270 calories per day, without being prescribed a diet or exercise program.

That's not to say that sleep treatment replaces obesity medication. It means that physiology is connected, and that asking about sleep is not a lifestyle nicety. It can be clinically relevant to why someone is gaining weight.

Medication history, eating behavior, depressionA prolonged low mood that interferes with life. and anxietyA state of worry or tension that disrupts focus and sleep., endocrine conditions, metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., alcohol, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function.... they all matter. And sometimes several of these are present at once.

Even “obesity” may contain multiple biological phenotypes

Researchers have also begun investigating whether what we call obesity contains distinct physiological and behavioral phenotypes. Mayo Clinic researchers have described patterns including impaired satiation, impaired satietySatiety is the sustained feeling of fullness between meals that delays hunger. Regulated by neuroendocrine signals like GLP-1, PYY, and leptin via the..., hedonic or emotional eating and reduced energy expenditure. In one clinical cohort, phenotype-guided anti-obesity pharmacotherapy was associated with substantially greater weight loss than standard medication selection.

The study is interesting, but it should not be oversold. A correction clarified that the treatment allocation was not randomized and that the findings require confirmation in rigorous randomized trials. The broader implication nevertheless remains important: obesity is heterogeneous, and investigators are actively studying whether identifying the mechanism can improve treatment selection.

That idea should feel intuitive. We already practice medicine this way almost everywhere else. A physician does not see fatigue and automatically prescribe a stimulant. Chest pain or Insomnia are not a diagnosis. High blood pressure prompts us to think about cardiovascular risk, medications, sleep apnea, kidney disease and other contributing factors. Why should weight be different?

FDA Approval Is Not the Same as a Clinical Diagnosis

Part of the confusion begins with the role of the U.S. Food and Drug Administration. FDA determines whether a medication has demonstrated sufficient safety and effectiveness to be marketed for a particular indication. Tirzepatide, for example, was approved for chronic weight management in qualifying adults in conjunction with reduced-calorie diet and increased physical activity. SemaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. has likewise received FDA approval for chronic weight management in specified populations. (FDA: Zepbound approval for chronic weight management)

That approval is extremely important, but it answers a specific regulatory question: whether the drug's benefits and risks justify its use in an indicated population. It does not establish a universal diagnostic process that every clinician must follow before deciding that an individual patient should receive the medication.

FDA has long made clear that it regulates medical products but generally does not regulate the practice of medicine itself. Medical practice remains largely governed through state licensing laws, professional standards, medical boards, malpractice law, and clinical judgment. (FDA: explanation of the agency's role) (FDA: regulation and the practice of medicine)

That separation exists for good reason. Physicians need the freedom to treat individual patients rather than follow rigid federal treatment algorithms. Yet the same structure creates an important gap in the modern GLP-1 market. FDA approval tells us that semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide can be appropriate treatments for obesity. It does not require every prescriber to complete a standardized assessment of sleep, mental health, eating behavior, metabolic status, medication-associated weight gain, endocrine conditions, body compositionThe balance of muscle, fat, and water in the body., stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., physical function, or the patient's weight trajectory before prescribing.

As a result, a medication can be entirely appropriate and FDA-approved while the depth of the clinical evaluation preceding its use varies enormously.

The American Diabetes Association Recommends a Much Broader Assessment

Modern obesity guidelines are moving in a very different direction from the light-touch prescribing model. The American Diabetes Association's 2026 Standards of Care in Overweight and Obesity recommend a comprehensive evaluation after overweight or obesity has been identified. The purpose of that evaluation is not merely to confirm BMI. It is to understand the patient's weight history, factors contributing to weight gain, obesity-related disease, medical and psychological conditions, previous treatment attempts, treatment barriers, social circumstances, and overall health before constructing a management plan. (American Diabetes Association: 2026 obesity evaluation standards)

The ADA framework includes assessment of mental health, including depressionA prolonged low mood that interferes with life. and anxietyA state of worry or tension that disrupts focus and sleep.; eating behavior and eating disorders; sleep duration and quality; stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function.; physical activity; nutrition; substance use; medications that may promote weight gain; metabolic disease; obesity-related complications; and relevant social or environmental factors. The guidelines specifically describe the value of a comprehensive biopsychosocial assessment.

That language matters because it reflects a fundamental shift in how obesity is increasingly understood. The question is no longer simply whether a person meets a BMI threshold for treatment. The more sophisticated question is what biological, psychological, behavioral, environmental, and medical factors are contributing to the condition, which complications are already present, and how those findings should shape treatment.

In other words, the clinical sequence should be assessment first and treatment selection second.

Canadian Obesity Guidelines Go Even Further: Identify the Root Causes

Canadian obesity authorities make the same point even more explicitly.

The Canadian Adult Obesity Clinical Practice Guidelines, developed through Obesity Canada and collaborating experts, recommend comprehensive assessment to identify the root causes of weight gain, the complications associated with obesity, and the barriers that may affect successful treatment. (Obesity Canada: Adult Clinical Practice Guidelines)

One of the most useful elements of the Canadian framework is the 4Ms approach, which evaluates obesity across several domains rather than treating body weight as an isolated variable.

The first domain is Mental Health, including mood, anxietyA state of worry or tension that disrupts focus and sleep., eating behavior, cognitive factors, psychological health, expectations, and the impact of weight stigma. The second is Metabolic Health, including diabetes risk, hypertension, dyslipidemia, fatty liver disease, endocrine and metabolic abnormalities, and other biological consequences or contributors. The third is Mechanical Health, which includes problems such as obstructive sleep apnea, osteoarthritis, pain, mobility limitations, and impaired physical function. The fourth concerns the patient's broader Milieu, including social circumstances, financial resources, living environment, and practical barriers affecting care. (Obesity Canada: detailed obesity assessment framework)

The broader Canadian model follows the sequence Ask, Assess, Advise, Agree, Assist. Assessment therefore precedes the decision about treatment, and treatment may include nutritional, behavioral, psychological, physical, pharmacologic, or surgical interventions depending on what the evaluation reveals. (Obesity Canada: Clinical Practice Guideline Quick Guide)

This is important because the Canadian framework does not treat medication as the organizing principle of obesity care. Medication is one possible intervention within a much larger diagnostic and therapeutic structure.

Why Obesity Requires a Whole-Person View

The clinical logic behind these guidelines is straightforward: body weight is regulated by interacting systems. Mental health and metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health. influence each other. Sleep affects hunger, appetite regulation, glucose metabolism, energy intake, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function. physiology, and decision-making. Medications prescribed for psychiatric, inflammatory, neurologic, and cardiovascular conditions can influence weight. Eating behavior may be affected by mood, reward circuitry, traumaA deeply distressing experience that leaves lasting psychological impact., stress, food environment, and habit. Hormonal and endocrine disorders may alter metabolism or appetite. Loss of muscle mass, physical inactivity, chronic pain, and poor sleep may reinforce one another. Treating weight without understanding those systems can therefore produce an incomplete picture of the patient.

DepressionA prolonged low mood that interferes with life. offers a useful example. A large longitudinal meta-analysis found a bidirectional relationship between obesity and depression: obesity was associated with an increased later risk of depression, while depression was associated with an increased later risk of obesity. (PubMed: Obesity and depression meta-analysis)

That finding does not mean obesity is primarily a psychiatric condition, nor that treating depressionA prolonged low mood that interferes with life. will necessarily lead to substantial weight loss. It does mean that mental health belongs inside a serious obesity assessment rather than outside it.

Sleep provides another example. In a randomized clinical trial published in JAMA Internal Medicine, adults with overweight who habitually slept fewer than 6.5 hours per night were assigned either to continue their usual sleep pattern or receive an intervention designed to extend sleep. Participants in the sleep-extension group reduced their average energy intake by approximately 270 calories per day, despite not being prescribed a diet or exercise intervention. (JAMA Internal Medicine: sleep extension and energy intake)

Again, the point is not that treating sleep replaces GLP-1 therapy. The point is that sleep can materially influence the biology and behavior involved in weight regulation, and therefore deserves attention when clinicians are trying to understand why a patient is gaining weight.

Medication history is equally important. The ADA specifically identifies commonly used medications that may promote weight gain, including certain antipsychotics, antidepressantsA medication that alters brain chemistry to relieve depression., glucocorticoids, anticonvulsants, and beta blockers, and recommends considering more weight-neutral alternatives when clinically appropriate. (ADA: Obesity and Weight Management Standards of Care 2026)

A patient who gained significant weight after starting a particular medication may still benefit from a GLP-1. But ignoring the contributing medication because an effective appetite-suppressing drug is available would be difficult to describe as comprehensive medical care.

The Effectiveness of GLP-1 Drugs Makes Better Diagnosis More Important, Not Less

GLP-1 medications work extremely well for many patients. That success is precisely why clinicians should resist allowing the medication to become a substitute for diagnosis. When a treatment is highly effective, there is a natural temptation to use improvement in the visible outcome as proof that the medical problem has been adequately understood. A patient loses substantial weight, metabolic markers improve, and both patient and clinician may reasonably regard the intervention as successful. Yet, weight loss alone does not tell us whether every clinically important contributor has been addressed.

A patient may lose weight while severe depressionA prolonged low mood that interferes with life. remains untreated. Another may lose weight while continuing to experience binge eating or disordered eating. Another may have undiagnosed obstructive sleep apnea. Another may remain chronically sleep-deprived. Another may continue taking a medication that substantially contributed to the original weight gain. Another may lose weight while losing excessive muscle or failing to improve physical conditioning. A patient's laboratory and metabolic profile may improve in some areas while other risks remain.

None of these examples automatically make the GLP-1 prescription inappropriate. They illustrate something more important: a successful prescription and comprehensive medical care are not the same thing. That distinction is central to the approach at Fountain Health.

Fountain Health's Approach to GLP-1 and Weight Management

Fountain Health is a multidisciplinary medical practice in New York City that approaches metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., mental health, sleep, nutrition, hormones, physical health, and other biological systems as interconnected parts of the same patient.

Our approach to GLP-1 treatment begins with a simple principle: the objective is not to determine how quickly a patient can qualify for semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. or tirzepatide. The objective is to understand enough of the patient's overall health to determine what treatment strategy makes clinical sense.

Depending on the individual, a comprehensive Fountain Health weight-management assessment may consider weight history and previous treatments, metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., relevant laboratory findings, medications, nutrition, eating behavior, mental health, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., sleep, body compositionThe balance of muscle, fat, and water in the body., physical activity and fitness, hormonal or endocrine contributors when clinically indicated, and the patient's broader goals and circumstances.

That does not mean every patient needs every test, every laboratory panel, or every specialist. Comprehensive medicine should not become indiscriminate testing. The purpose of a serious clinical evaluation is to identify what matters, what requires further investigation, what can safely be left alone, and what should influence treatment.

For some patients, that assessment may strengthen the case for GLP-1 therapy. For others, it may identify conditions that should be treated at the same time. In some cases, it may suggest that another problem should be addressed before medication becomes the first intervention. The important point is that the answer should emerge from the patient's clinical picture rather than from the product the patient happened to encounter online.

Long-Term GLP-1 Treatment Makes Comprehensive Care Even More Important

Obesity is increasingly understood as a chronic disease, and GLP-1 treatment may need to be long-term. The STEP 1 extension study demonstrated that participants who stopped semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation. regained a substantial proportion of the weight they had lost during treatment, with many cardiometabolic improvements moving back toward baseline. (PubMed: STEP 1 extension study)

Similar findings emerged from the SURMOUNT-4 trial involving tirzepatide. Participants who discontinued treatment and were switched to placebo regained substantial weight, while those who continued tirzepatide maintained and extended their weight reduction. (JAMA: SURMOUNT-4 tirzepatide trial)

These studies should not be interpreted as evidence that GLP-1 medications fail. They show the opposite: the drugs exert a meaningful biological effect, and removing that effect can lead to recurrence of the disease. They also expose the weakness of a model whose entire treatment architecture is simply: prescribe > lose weight > refill. The patient still needs a long-term plan.

What happens to sleep? Nutrition? Strength and body compositionThe balance of muscle, fat, and water in the body.? Metabolic markers? Mental health? Eating patterns? Medication adherence? The conditions that existed before treatment? The conditions that emerge during treatment? That is where weight-loss treatment becomes actual longitudinal medical care. A prescription can initiate treatment. It cannot replace longitudinal care. And, if it does, it subjects a patient to endless medication without a meaningful recovery.

The Larger Problem Is Prescription-First Medicine

The GLP-1 boom exposes a broader problem that extends beyond obesity.

Modern healthcare has become exceptionally good at making interventions easier to deliver. TelehealthMedical care delivered via phone or video., digital intake forms, automated scheduling, remote prescribing, direct-to-consumer marketing, and mail-order pharmacies can all improve access when used appropriately.

But diagnosis remains difficult to scale.

Understanding why a patient feels unwell takes time. It often requires history, clinical judgment, appropriate testing, follow-up, and sometimes collaboration across specialties. The correct conclusion may also be commercially inconvenient: a patient may not need the treatment that initially brought that person through the door.

That creates a structural tension in modern healthcare. The easier it becomes to deliver a treatment, the easier it becomes to mistake access to treatment for quality of care.

GLP-1 medicine makes that tension unusually visible because the drugs are highly effective, consumer demand is enormous, and the commercial infrastructure around them has expanded with remarkable speed.

Fountain Health was built around the opposite idea: advanced medicine should use better technology and better therapeutics without abandoning the process of understanding the patient.

Diagnosis Before Prescription

The debate over GLP-1 medications should not be reduced to whether these drugs are good or bad. That is no longer a useful medical question. SemaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation., tirzepatide, and future generations of metabolic drugs are likely to remain important parts of obesity treatment. The more important question is what kind of medicine surrounds them.

The American Diabetes Association recommends comprehensive biopsychosocial assessment before developing an obesity management plan. Canadian obesity authorities explicitly recommend evaluating the root causes and complications of obesity across mental, metabolic, mechanical, and environmental dimensions. FDA, meanwhile, regulates the drugs themselves but generally leaves the practice of medicine to clinicians and state authorities. Taken together, those facts expose the central issue.

We now have increasingly sophisticated obesity treatments and an increasingly sophisticated understanding of obesity, but the healthcare system can still deliver the first without requiring much of the second.

At Fountain Health, we believe the better model is straightforward: understand the patient before choosing the treatment.

That may lead to GLP-1 therapy. It may lead to treatment of several connected conditions at once. It may change which intervention should come first. In every case, the purpose is the same: to make the treatment fit the patient rather than making the patient fit the prescription.

The future of obesity medicine should not be less medication. It should be better medicine.

GLP-1 is a powerful treatment. The practice of medicine is determining when, why, and how a particular person should receive it.

Clinical References

American Diabetes Association — Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026
The ADA's current framework for comprehensive obesity evaluation, including weight history, medical and psychological conditions, eating behavior, sleep, stressThe body's response to external demands. Chronic stress disrupts hormones, sleep, and immune function., medications, metabolic healthHow efficiently your body manages blood sugar, cholesterol, and energy balance. A strong predictor of long-term health., and social factors.
Read the ADA 2026 obesity evaluation standards

American Diabetes Association — Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026
Current recommendations involving obesity pharmacotherapy, obesity-related complications, and medications associated with weight gain.
Read the ADA obesity and pharmacotherapy standards

Obesity Canada — Canadian Adult Obesity Clinical Practice Guidelines
Canadian guidelines emphasizing comprehensive assessment of root causes of weight gain, complications, and barriers to treatment.
Read the Canadian Adult Obesity Clinical Practice Guidelines

Obesity Canada — Assessment of People Living With Obesity
Detailed discussion of the 4Ms framework addressing Mental, Metabolic, Mechanical, and environmental or socioeconomic dimensions of obesity.
Read the Obesity Canada assessment chapter

Obesity Canada — Clinical Practice Guideline Quick Guide
Summary of the Ask, Assess, Advise, Agree, and Assist framework for individualized obesity management.
Read the clinical guideline quick guide

U.S. Food and Drug Administration — FDA's Role in Medical Products and Medical Practice
FDA explanation of the distinction between regulation of medical products and regulation of the practice of medicine.
Read the FDA explanation

U.S. Food and Drug Administration — New Drug Regulations and the Practice of Medicine
FDA discussion of the role of state medical-practice laws and physician judgment after a drug reaches the market.
Read the FDA regulatory discussion

U.S. Food and Drug Administration — Zepbound Approval for Chronic Weight Management
FDA's description of tirzepatide's approved indication for chronic weight management.
Read the FDA approval announcement

Luppino et al. — Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Evidence of a bidirectional longitudinal association between depressionA prolonged low mood that interferes with life. and obesity.
Read the PubMed record

Tasali et al. — Effect of Sleep Extension on Objectively Assessed Energy Intake Among Adults With Overweight in Real-Life Settings
Randomized clinical trial showing lower daily energy intake among adults assigned to extend habitual sleep.
Read the JAMA Internal Medicine study

Wilding et al. — Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: STEP 1 Trial Extension
Follow-up evidence describing weight regain after discontinuation of semaglutideA GLP-1 agonist medication used for weight loss and blood sugar regulation..
Read the STEP 1 extension

Aronne et al. — Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4
Randomized withdrawalSymptoms that arise when reducing or stopping alcohol, drugs, or certain medications. study demonstrating substantial weight regain after discontinuation compared with continued tirzepatide treatment.
Read the SURMOUNT-4 study

Written by Fountain Health Clinical Editorial Team
Medically reviewed by Doreen Zarfati, MD
Updated: September 2026

Fountain Health is a multidisciplinary medical practice in New York City providing care across mental health, metabolic health, longevity, sleep, nutrition, fitness, and related areas of advanced medicine. This article is for educational purposes and does not replace individualized medical evaluation.